Replies to post #182 on Equity Field Notes from temporal sources

[DanWebzster]

ONCS hired former AVXS CEO Daniel OConnor. How responsible was he for AVXS technological innovation? I don't know.

ONCS technology involves localized injection of a cytokine into tumor followed by the delivery of electrical pules

Preliminary data in the combo therapy with Keytruda will be presented in 2018.

Breakthrough Therapy & Fast Track Designations are possibilities.

2/28/18, Cash = $37.6mn giving them a runway into Q4/2018.